Synergistic targeting systems for cancer precision medicine: co- and sequential binding to multiple tumor biomarkers
Source abstract
Abstract
Cancer poses a crucial risk to human health because of its complexity and heterogeneity. Precision medicine has been widely noticed as an emerging concept, which brings great opportunities to improve cancer diagnosis and treatment. Here, tumor biomarkers and corresponding diseased-site targeting strategies are emphasized, recognition ligands with high specificity and affinity are summarized and the common and creative approaches of precision medicine are discussed. Further, precision targeting systems (PTS) based on different numbers of tumor biomarkers, including single-, dual- and triple biomarker-based PTS, are reviewed. Based on the binding of multiple recognition probes to different markers especially in a sequential manner, the advantages of synergistic targeting strategies in cancer diagnosis and treatment are separately highlighted. In addition, the application of single- and multi-marker-based PTS in detecting the expression level of specific molecules, inducing the dysfunctional species within subcellular locations (e.g., nucleus and mitochondria) is summarized. Finally, the challenges and future perspective of PTS based on multiple biomarkers are discussed. The review indicates that further improvement of precision medicine relies on new breakthroughs in the discovery of biomarkers exclusive to diseased cells and their ingenious combination, which will become a cornerstone of biomedical studies and clinical precision medicine. STATEMENT OF SIGNIFICANCE: To a large degree, significant advancement in precision medicine is highly dependent on the development of precision targeting systems (PTS) based on the recognition of multi-ligands to different targets, coupled with a deep understanding of their operational mechanisms for tumor cell recognition and drug delivery. This review summarizes common tumor biomarker receptors and their specific recognition ligands, the design of targeted delivery systems based on single or multiple tumor biomarkers (especially sequential targeting systems), the molecular mechanisms for their operation, and their applications within subcellular structures. These innovations deepen our understanding of the design and operational mechanisms of PTS and reveal their potential to overcome tumor heterogeneity. By emphasizing the unique advantages of precision targeting systems, this review is expected to efficiently highlight the precision medicine of cancer patients and offered a new opportunity for cancer prevention, treatment, and prognosis in a precise manner.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Cancer Cells and Metastasis · Nanoplatforms for cancer theranostics · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Recent advances in active targeting of nanomaterials for anticancer drug delivery10.1016/j.cis.2021.102509 ↗
2. Nanotechnology for multimodal synergistic cancer therapy10.1021/acs.chemrev.7b00258 ↗
3. Surgical management of high-risk, localized prostate cancer10.1038/s41585-020-00384-7 ↗
4. Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer10.1038/s41571-021-00579-w ↗
5. Optimizing pharmacokinetics of intravesical chemotherapy for bladder cancer10.1038/s41585-019-0220-4 ↗
6. Clinical development and potential of photothermal and photodynamic therapies for cancer10.1038/s41571-020-0410-2 ↗
7. Advanced biotechnology-assisted precise sonodynamic therapy10.1039/D1CS00403D ↗
8. T-cell-derived nanovesicles for cancer immunotherapy10.1002/adma.202101110 ↗
9. Cancer-associated, stimuli-driven, turn on theranostics for multimodality imaging and therapy10.1002/adma.201606857 ↗
10. Biodegradable silicon nanoneedles delivering nucleic acids intracellularly induce localized in vivo neovascularization10.1038/nmat4249 ↗
11. Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer10.1038/s41568-022-00454-5 ↗
12. Theranostic near-infrared-IIb emitting nanoprobes for promoting immunogenic radiotherapy and abscopal effects against cancer metastasis10.1038/s41467-021-27485-0 ↗
13. Global access to radiotherapy services: have we made progress during the past decade?10.1200/JGO.2015.001545 ↗
14. Nanoscale coordination polymers induce immunogenic cell death by amplifying radiation therapy mediated oxidative stress10.1038/s41467-020-20243-8 ↗
15. Toxicity of doxorubicin (Dox) to different experimental organ systems10.1016/j.lfs.2018.03.023 ↗
16. Docetaxel activity in the era of life-prolonging hormonal therapies for metastatic castration-resistant prostate cancer10.1016/j.eururo.2016.05.002 ↗
17. Paclitaxel and its formulations10.1016/S0378-5173(01)00986-3 ↗
18. Cisplatin in cancer therapy: molecular mechanisms of action10.1016/j.ejphar.2014.07.025 ↗
19. Hollow mesoporous silica nanoparticles with tunable structures for controlled drug delivery10.1021/acsami.6b13876 ↗
20. Stress-inducible gene Atf3 in the noncancer host cells contributes to chemotherapy-exacerbated breast cancer metastasis10.1073/pnas.1700455114 ↗
21. Organelle-targeting metal complexes: from molecular design to bio-applications10.1016/j.ccr.2017.10.022 ↗
22. Nanomaterials for cancer precision medicine10.1002/adma.201705660 ↗
23. Targeting cancer metabolism in the era of precision oncology10.1038/s41573-021-00339-6 ↗
24. The cancer genome10.1038/nature07943 ↗
25. The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells10.1186/s12943-023-01844-5 ↗
26. Dual-targeted nanoparticle-in-microparticle system for Ulcerative Colitis therapy10.1002/adhm.202301518 ↗
27. Programmable and multiparameter DNA-based logic platform for cancer recognition and targeted therapy10.1021/ja509263k ↗
28. Light-driven cascade mitochondria-to-nucleus photosensitization in cancer cell ablation10.1002/advs.202004379 ↗
29. GSH and H2O2 Co-activatable mitochondria-targeted photodynamic therapy under normoxia and hypoxia10.1002/anie.202003895 ↗
30. Pyridine-embedded phenothiazinium dyes as lysosome-targeted photosensitizers for highly efficient photodynamic antitumor therapy10.1021/acs.jmedchem.0c00280 ↗
31. A self-assembled Ru-Pt metallacage as a lysosome-targeting photosensitizer for 2-photon photodynamic therapy10.1073/pnas.1912549116 ↗
32. Reversing multidrug resistance by intracellular delivery of Pluronic® P85 unimers10.1016/j.biomaterials.2013.08.032 ↗
33. Two-dimensional nanomaterials for biomedical applications: emerging trends and future prospects10.1002/adma.201502422 ↗
34. In response to precision medicine: current subcellular targeting strategies for cancer therapy10.1002/adma.202209529 ↗
35. Current studies and future promises of PD-1 signal inhibitors in cervical cancer therapy10.1016/j.biopha.2022.114057 ↗
36. A meta-analysis of the difference in response to trastuzumab-deruxtecan (T-DXd) based on HER2 immunohistochemistry (IHC) in HER2 low metastatic breast cancer (mBC)
37. Nanomaterials for cancer precision medicine
38. Targeted covalent modification strategies for drugging the undruggable targets10.1021/acs.chemrev.4c00745 ↗
39. The coming decade in precision oncology: six riddles10.1038/s41568-022-00529-3 ↗
40. Smart nucleic acid nanodrug delivery system for precision therapeutics10.1016/j.ccr.2025.216673 ↗
41. Stimuli-responsive delivery systems using carbohydrate polymers: a review10.1016/j.ijbiomac.2025.142648 ↗
42. Recent advances in lipid nanoparticles: nucleic acid therapeutics and targeting strategies10.1002/smll.202506812 ↗
43. Functional materials for subcellular targeting strategies in cancer therapy: progress and prospects
44. Challenges and material innovations in drug delivery to central nervous system tumors10.1016/j.biomaterials.2025.123180 ↗
45. Advanced oral drug delivery systems for gastrointestinal targeted delivery: the design principles and foundations10.1186/s12951-025-03479-8 ↗
46. Illuminating gene delivery: insights into the light-induced gene delivery systems with emphasis on mRNA therapeutics10.1016/j.mattod.2025.06.034 ↗
47. A new initiative on precision medicine10.1056/NEJMp1500523 ↗
48. Resolving genetic heterogeneity in cancer10.1038/s41576-019-0114-6 ↗
49. The cancer genome10.1038/nature07943 ↗
50. Clonal evolution in cancer10.1038/nature10762 ↗
51. Assessing therapy response in patient-derived xenografts10.1126/scitranslmed.abf4969 ↗
52. Current status and perspectives of patient-derived xenograft models in cancer research10.1186/s13045-017-0470-7 ↗
53. Tumor biomarkers for diagnosis, prognosis and targeted therapy10.1038/s41392-024-01823-2 ↗
54. Tumor biomarkers for diagnosis, prognosis and targeted therapy
55. Vascular tumor burden as a new quantitative CT biomarker for predicting metastatic RC response to antiangiogenic therapy10.1148/radiol.2016160143 ↗
56. Recent advances in targeted drug delivery strategy for enhancing oncotherapy10.3390/pharmaceutics15092233 ↗
57. Ligand-targeted therapeutics in anticancer therapy10.1038/nrc903 ↗
58. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology10.1016/j.addr.2013.11.009 ↗
59. Rigidified DNA triangle-protected molecular beacon from endogenous nuclease digestion for monitoring microRNA expression in living cells10.1021/acssensors.0c00212 ↗
60. Periodically ordered, nuclease-resistant DNA nanowires decorated with cell-specific aptamers as selective theranostic agents10.1002/anie.202004805 ↗
61. Simple self-assembled targeting DNA nano sea urchin as a multivalent drug carrier10.1021/acsabm.0c00462 ↗
62. Y-shaped backbone-rigidified triangular DNA scaffold-directed stepwise movement of a DNAzyme walker for sensitive MicroRNA imaging within living cells10.1021/acs.analchem.9b03784 ↗
63. Bioinformatics for cancer immunotherapy target discovery10.1007/s00262-014-1627-7 ↗
64. Cell-specific aptamers as potential drugs in therapeutic applications: a review of current progress10.1016/j.jconrel.2022.04.039 ↗
65. Aptamer-based targeted therapy10.1016/j.addr.2018.08.005 ↗
66. Aptamer-based detection of circulating targets for precision medicine10.1021/acs.chemrev.0c01140 ↗
67. Identifying biomarkers and therapeutic targets by Multiomic Analysis for HNSCC: precision medicine and Healthcare management
68. Target profiling of small molecules by chemical proteomics10.1038/nchembio.216 ↗
69. Personalization of prostate cancer therapy through phosphoproteomics10.1038/s41585-018-0014-0 ↗
70. Epigenetics of colorectal cancer: biomarker and therapeutic potential10.1038/s41575-019-0230-y ↗
71. Simultaneous targeting of CD14 and factor XIa by a fusion protein consisting of an anti-CD14 antibody and the modified second domain of bikunin improves survival in rabbit sepsis models10.1016/j.ejphar.2017.02.045 ↗
72. Dual-aptamer recognition of DNA logic gate sensor-based specific exosomal proteins for ovarian cancer diagnosis10.1021/acssensors.4c00270 ↗
73. The CD44-mediated uptake of hyaluronic acid-based carriers in macrophages
74. Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition
75. Elucidation and structural modeling of CD71 as a molecular target for cell-specific aptamer binding10.1021/jacs.9b03720 ↗
76. Antitumor efficacy of dual blockade of EGFR signaling by Osimertinib in combination with Selumetinib or Cetuximab in activated EGFR Human NCLC tumor models10.1016/j.jtho.2018.02.025 ↗
77. Comparative experimental/theoretical studies on the EGFR dimerization under the effect of EGF/EGF analogues binding: highlighting the importance of EGF/EGFR interactions at site III interface10.1016/j.ijbiomac.2018.04.066 ↗
78. Multi-targeting nano-systems targeting heterogeneous cancer cells for therapeutics and biomarker detection10.1002/adhm.202202155 ↗
79. Arginine methylation of EGFR: a new biomarker for predicting resistance to anti-EGFR treatment
80. Dynamical rearrangement of Human epidermal growth factor receptor 2 upon antibody binding: effects on the dimerization10.3390/biom9110706 ↗
81. TfR aptamer enhanced blood-brain barrier penetration of biomimetic nanocomplexes for intracellular transglutaminase 2 imaging and silencing in glioma
82. Using DNA aptamer probe for immunostaining of cancer frozen tissues10.1021/ac504175h ↗
83. Bispecifc aptamer-decorated and light-triggered nanoparticles targeting tumor and stromal cells in breast cancer derived organoids: implications for precision phototherapies (vol 43, 92, 2024)
84. Peptide-targeted nanoglobular Gd-DOTA monoamide conjugates for magnetic resonance cancer molecular imaging10.1021/bm901352v ↗
85. Overcoming the lack of oral availability of cyclic hexapeptides: design of a selective and orally available ligand for the integrin αvβ310.1002/anie.201709709 ↗
86. Discovery of the first potent and selective α(v)β(5) integrin inhibitor based on an amide-containing core10.1016/j.ejmech.2020.112719 ↗
87. Shell penetration/free energy-driven crosstalk between intelligent DNA nanomachines for ultrasensitive detection of circulating tumor cells10.1016/j.nantod.2023.101808 ↗
88. Ribbon of DNA lattice on gold nanoparticles for selective drug delivery to cancer cells10.1002/anie.202005624 ↗
89. MUC1 aptamer targeted SERS nanoprobes10.1002/adfm.201606632 ↗
90. Precision-guided missile-like DNA nanostructure containing warhead and guidance control for aptamer-based targeted drug delivery into cancer cells in vitro and in vivo10.1021/jacs.9b09782 ↗
91. Advances in targeting the folate receptor in the treatment/imaging of cancers10.1039/C7SC04004K ↗
92. Dual-targeted enzyme-sensitive hyaluronic acid nanogels loading paclitaxel for the therapy of breast cancer10.1016/j.carbpol.2022.119785 ↗
93. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF06747143) in chronic lymphocytic leukemia10.1186/s13045-017-0435-x ↗
94. CXCR4-guided liposomes regulating hypoxic and immunosuppressive microenvironment for sorafenib-resistant tumor treatment
95. A targeting delivery system for effective genome editing in leukemia cells to reverse malignancy10.1016/j.jconrel.2022.02.012 ↗
96. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer
97. Precise design of nanomedicines: perspectives for cancer treatment10.1093/nsr/nwz012 ↗
98. Nanoparticle and targeted systems for cancer therapy10.1016/j.addr.2012.09.033 ↗
99. Cancer nanomedicine: progress, challenges and opportunities10.1038/nrc.2016.108 ↗
100. Non-viral vectors for gene-based therapy10.1038/nrg3763 ↗